Mesembrenone is a naturally occurring Kanna alkaloid with an unusual research profile: in laboratory experiments it interacted with both the serotonin transporter (SERT) and phosphodiesterase-4 (PDE4). That makes it scientifically interesting, but it does not make mesembrenone an approved antidepressant, a prescription PDE4 medicine, or a complete explanation for what Kanna does.
The evidence has sharp boundaries. Researchers have tested purified mesembrenone in cell-free and cellular assays, human-liver preparations, rat metabolism experiments and mouse pharmacokinetic work. Small studies in living people have tested multi-constituent Kanna extracts—not isolated mesembrenone. Whole plant material, fermented material, standardized extracts and a purified molecule therefore cannot share one evidence label.
This guide is educational, nonmedical and intended for adults 21 and older. It provides no serving instructions and does not tell anyone to start, stop or replace a medicine.
The central finding: mesembrenone was the strongest PDE4 inhibitor among three purified Kanna alkaloids in a widely cited 2011 laboratory comparison, while mesembrine showed much stronger SERT affinity. Mesembrenone had measurable activity at both targets, but no controlled human trial has established the effects, exposure or safety of isolated mesembrenone.
Mesembrenone in one minute
- Mesembrenone is one alkaloid found in some Kanna material; it is not a synonym for Kanna.
- Its molecular formula is C17H21NO3, and its relative molecular mass is about 287.35.
- In one comparative laboratory study, purified mesembrenone inhibited PDE4 more strongly than purified mesembrine or mesembrenol.
- The same research found that mesembrenone interacted with SERT, although mesembrine had substantially higher measured SERT affinity.
- A detailed metabolism study used rat urine, pooled human-liver preparations and recombinant enzymes—not a living-human pharmacokinetic cohort.
- A mouse study found low oral exposure under its experimental conditions. Mouse exposure cannot be converted into a human serving, effect or safety conclusion.
- Human Kanna studies have used standardized extracts containing multiple constituents. They do not establish what isolated mesembrenone does in people.
- Mesembrenone and Δ7-mesembrenone are positional isomers, not interchangeable names.
What is mesembrenone?
Mesembrenone is a nitrogen-containing alkaloid reported in Kanna, a southern African botanical generally identified in older scientific literature as Sceletium tortuosum. Current botanical databases accept Mesembryanthemum tortuosum L. and list Sceletium tortuosum (L.) N.E.Br. as a synonym. Both names therefore appear in legitimate research.
The molecule has formula C17H21NO3 and a molecular weight of approximately 287.35 g/mol. It belongs to the mesembrine-type alkaloid family, but it differs structurally from mesembrine, mesembrenol, mesembranol and related compounds. Those differences can alter target affinity, metabolism, chemical stability and analytical retention.
Some recent papers call the ordinary compound Δ6-mesembrenone to distinguish the position of its double bond from Δ7-mesembrenone. Older papers often say simply “mesembrenone.” Authors and laboratories need to specify what they mean because the two compounds have the same elemental formula and nominal mass.
Identity source: PubChem’s mesembrenone record.
Mesembrenone is not the same research object as Kanna
| Research object | What it contains | What the evidence can support | What it cannot establish |
|---|---|---|---|
| Authenticated Kanna plant material | A variable mixture of alkaloids and non-alkaloid constituents | Chemistry of the sampled species, plant part, location and harvest | The profile of every retail product |
| Fermented Kanna | Plant material changed by one defined process | Before-and-after chemistry under that process | One universal “fermented” composition |
| Standardized Kanna extract | Multiple constituents adjusted to a specification | Results for that named extract and tested batch | Effects of pure mesembrenone |
| Isolated mesembrenone | One purified, structurally defined alkaloid | Compound-specific assay, metabolism and animal-PK results | Whole-plant or extract effects in people |
| Δ7-mesembrenone | A positional isomer with the same formula as mesembrenone | Results for the correctly identified isomer | Automatic substitution for mesembrenone |
This separation is more than terminology. A target result for a purified molecule does not reveal how much of that molecule is present in a leaf sample, survives preparation, enters the bloodstream or reaches tissue. Likewise, a result for a multi-constituent extract cannot be assigned to mesembrenone unless the study design isolates its contribution.
For the mixture-level picture, see Kiody’s Kanna alkaloids, fermentation, SERT and PDE4 guide. Kiody’s mesembrine evidence guide covers the related compound whose SERT profile differs from mesembrenone’s. Readers new to the plant can begin with what Kanna is.
Mesembrenone vs mesembrine
Mesembrenone and mesembrine are related but distinct molecules. Mesembrenone has two fewer hydrogen atoms and contains an additional unsaturation. In the best-known direct assay comparison, they also produced different relative target profiles.
| Alkaloid | Formula | Key distinction | Best-supported laboratory emphasis |
|---|---|---|---|
| Mesembrenone | C17H21NO3 | Unsaturated ketone | Dual SERT and PDE4 activity; strongest PDE4 result among three alkaloids in Harvey et al. |
| Mesembrine | C17H23NO3 | Two more hydrogens and a different oxidation state | Highest SERT affinity among the three alkaloids in Harvey et al.; much weaker PDE4 result |
| Mesembrenol | C17H23NO3 | Shares a formula with mesembrine but not the same structure | Weaker SERT and PDE4 findings in that comparison |
| Δ7-mesembrenone | C17H21NO3 | Double bond in another position | Prominent in some processing studies; compound-specific human pharmacology remains sparse |
| Mesembranol | C17H25NO3 | More hydrogenated family member | Detection does not establish mesembrenone exposure or activity |
The practical conclusion is not that one alkaloid is “better.” It is that chemical ratios can matter. A mesembrine-dominant botanical or extract cannot automatically be assigned a mesembrenone-dominant PDE4 profile. Conversely, identifying mesembrenone does not prove a clinical outcome.
How much mesembrenone occurs in Kanna?
No universal concentration is supported. Shikanga and colleagues chemically profiled 151 wild specimens from 31 South African locations and eight commercial formulations. The study identified five broad chemotype clusters, including material characterized by mesembrenone dominance and other material dominated by mesembrine, mesembrenol or no detected mesembrine-type alkaloids. Total measured alkaloids in the wild specimens ranged from 0.11% to 1.99% of dry weight.
Those data show genuine botanical diversity, not a specification for every modern product. Species authentication, plant part, location, season, cultivation, storage, fermentation, extraction and analytical method can all affect the reported profile. “Contains Kanna” does not answer how much mesembrenone is present in a particular lot.
A defensible product-specific claim therefore needs batch-specific testing with an appropriate reference standard and a method capable of separating related alkaloids. A “total alkaloid” result alone cannot show whether mesembrenone is dominant, minor or absent.
Primary source: Shikanga et al., 2012.
What does the SERT research show?
SERT is the transporter that returns serotonin from the extracellular space to the presynaptic cell. Inhibiting SERT can slow serotonin reuptake in a defined test system. It does not demonstrate that a compound treats depression, raises mood, creates serotonin or produces a predictable effect in a person.
Harvey and colleagues tested a standardized Sceletium extract and purified mesembrine, mesembrenone and mesembrenol. Purified mesembrenone showed submicromolar activity at SERT, while mesembrine had the highest reported affinity. The reported inhibition constants were approximately 27 nM for mesembrenone and 1.4 nM for mesembrine, making mesembrine about twenty times more potent by that assay-specific comparison. Mesembrenol was reported at 63 nM.
An inhibition constant, or Ki, is a model-based measure of affinity under specified laboratory conditions. It is not a human blood concentration, serving size, effect threshold or safety boundary. Different assay systems, substrates, membranes and calculation methods can produce different values.
The supported conclusion is narrow: purified mesembrenone interacted with SERT in the reported assay, but less strongly than purified mesembrine. The experiment did not establish clinical selectivity, brain exposure, duration, therapeutic benefit or long-term safety.
Primary source: Harvey et al., 2011.
Why PDE4 is central to the mesembrenone story
PDE4 enzymes break down cyclic adenosine monophosphate, or cAMP, an intracellular signaling messenger. In the same 2011 experiments, mesembrenone was the most active PDE4 inhibitor among the three purified Kanna alkaloids tested. Its reported half-maximal inhibitory concentration was about 470 nM, compared with approximately 7,800 nM for mesembrine and 10,000 nM for mesembrenol.
These values make mesembrenone the clearest PDE4 lead within that limited comparison. They do not prove a human cognitive, emotional or inflammatory effect. An IC50 is the concentration that reduces a measured signal by half in one assay; it is not a clinical exposure target. The experiment also did not characterize all PDE4 subtypes, tissue distribution, free drug concentration, metabolites or the relationship between target engagement and tolerability in people.
Approved PDE4 medicines such as roflumilast and apremilast have defined pharmaceutical formulations, regulatory indications, human pharmacokinetics and extensive adverse-event data. Sharing an enzyme target does not make mesembrenone equivalent to either medicine. Chemical structure, potency, selectivity, distribution, metabolism and clinical evidence all differ.
Is mesembrenone an SSRI or a PDE4 medicine?
Neither label is sufficiently precise. It is accurate to say that purified mesembrenone inhibited SERT and PDE4 in specified preclinical assays. “SSRI” and “PDE4 medicine,” however, are also pharmaceutical categories associated with characterized products, approved uses, controlled human studies, manufacturing standards and known dose–exposure relationships.
Mesembrenone has no comparable isolated-compound clinical dossier. It has not been shown to match the selectivity, exposure, efficacy, adverse-event profile or interaction risk of an approved drug. Calling it a “natural SSRI” or “natural PDE4 drug” turns a mechanistic observation into a clinical claim that the research does not support.
The same caution applies to Kanna products. A product’s mesembrenone content and bioavailability may be unknown, and other constituents may contribute to or oppose an observed effect. The target profile of one purified alkaloid cannot classify an entire botanical mixture.
How is mesembrenone metabolized?
Meyer and colleagues isolated mesembrenone and mesembrine from plant material, confirmed their identities using nuclear magnetic resonance, and studied metabolism with rat urine, pooled human-liver preparations and recombinant cytochrome P450 enzymes. They used gas chromatography–mass spectrometry, liquid chromatography–multistage mass spectrometry and high-resolution methods to characterize products.
Mesembrenone underwent O-demethylation, N-demethylation, reduction, hydroxylation and combinations of these reactions. Conjugated products were also observed. In the recombinant-enzyme experiments, CYP2C9, CYP2C19 and CYP2D6 contributed to O-demethylation; CYP2C19, CYP2D6 and CYP3A4 contributed to N-demethylation. The investigators proposed N-demethylated and N-demethyl-dihydrogenated products as useful urinary markers in their rat model.
These findings identify plausible routes, not a complete human exposure curve. Pooled liver preparations cannot reproduce absorption, intestinal metabolism, blood flow, protein binding, tissue distribution, renal elimination or person-to-person variation. A compound being metabolized by a CYP enzyme also does not prove that it inhibits or induces that enzyme enough to cause a clinical drug interaction.
Primary source: Meyer et al., 2015.
What does the mouse pharmacokinetic study add?
Manda and colleagues developed a UHPLC–quadrupole time-of-flight mass-spectrometry method for mesembrine and mesembrenone in mouse plasma. The reported lower limit of quantification was 10 ng/mL, extraction recovery was 87% to 93%, accuracy ranged from 89.5% to 106%, and precision was below 12.6% under the validation conditions.
The method was then applied to intravenous and oral mouse pharmacokinetic experiments. The researchers reported poor oral bioavailability, with oral plasma concentrations below the method’s detection capability under their study conditions. This is valuable formulation and method-development evidence, but it is not a human result.
Species, route, formulation, gastrointestinal physiology, liver metabolism and sampling design all affect exposure. The mouse finding cannot be converted into a human serving, and it does not prove that every botanical or extract produces negligible human exposure. The study’s accessible abstract does not provide a living-human comparison.
The publication reported support from the U.S. Food and Drug Administration through award U01 FD004246. Funding source should be considered alongside the design and data; it does not determine whether the findings are correct.
Primary source: Manda et al., 2017.
Has isolated mesembrenone been studied in humans?
This evidence review did not locate a controlled study that administered purified mesembrenone to people and reported a validated plasma concentration–time profile or clinical outcome. There is no established isolated-compound Cmax, Tmax, half-life, clearance, oral bioavailability, receptor occupancy or dose–response curve in humans.
That absence is a central limitation. Laboratory potency cannot tell us whether unbound mesembrenone reaches a relevant human tissue concentration, how long it remains there or whether metabolites contribute to the observed biology. It also prevents reliable comparisons of onset, duration and interaction magnitude.
Small human studies do exist for selected standardized Kanna extracts. Those extracts contained multiple alkaloids and other constituents. Their results cannot be relabeled as isolated-mesembrenone evidence.
What the key studies actually tested
| Study | Design and sample | Tested material | What it supports | Main limitation |
|---|---|---|---|---|
| Harvey et al., 2011 | In-vitro transporter and enzyme assays | Standardized extract plus purified mesembrine, mesembrenone and mesembrenol | Assay-specific SERT and PDE4 activity | No living-human exposure or outcome data |
| Meyer et al., 2015 | Rat urine, pooled human-liver preparations and recombinant CYP enzymes | Purified mesembrenone and mesembrine | Candidate metabolites, enzyme routes and analytical markers | Not a human PK or interaction study |
| Manda et al., 2017 | Validated mouse-plasma method and mouse PK experiments | Mesembrenone and mesembrine | Mouse exposure and method performance | Species and route limits; no human cohort |
| Nell et al., 2013 | Randomized double-blind placebo-controlled study; 37 healthy adults over three months | One standardized multi-constituent extract | Tolerability observations for that product | Not pure mesembrenone; groups of 12, 12 and 13; not powered for rare events |
| Terburg et al., 2013 | Double-blind crossover pharmaco-fMRI; 16 healthy medication-free students | One standardized multi-constituent extract | Acute BOLD and connectivity findings for that extract | Small healthy sample; imaging signal is not clinical benefit |
In the 37-participant tolerability study, groups received placebo or one of two amounts of a standardized extract. The investigation was not designed to isolate mesembrenone or demonstrate treatment efficacy. In the 16-participant imaging study, a standardized extract altered selected blood-oxygen-level-dependent signals and connectivity measures under specific conditions. BOLD is an indirect imaging signal, not a direct serotonin measurement and not proof of treatment.
The Terburg study reported support from H.L. Hall and Sons and a Netherlands research grant; one author was an officer of the company that developed the tested extract. The Harvey paper included an author affiliated with the extract developer. Such disclosures do not automatically invalidate data, but they are relevant when independent replication is limited.
Human extract sources: Nell et al., 2013 and Terburg et al., 2013.
Does fermentation increase or decrease mesembrenone?
No single direction applies to every process. Chen and Viljoen measured alkaloids before and after a controlled fermentation and found that mesembrine increased in their samples while mesembrenone generally decreased, although starting and final values varied across material. Their mesembrenone measurements spanned approximately 8.00–33.0 micrograms/mL before fermentation and 1.30–32.7 micrograms/mL afterward.
Other work complicates the picture. Patnala and Kanfer observed a decline in mesembrine and an increase in Δ7-mesembrenone under their simulated kougoed preparation. A 2024 study revisiting natural fermentation reported time-dependent losses and shifts among Δ6-mesembrenone, Δ7-mesembrenone and other alkaloids, with differences between sterile and inoculated conditions.
The studies are not interchangeable: starting chemotype, plant part, moisture, temperature, light, oxygen, microorganisms, duration and analytical timing differ. The sound conclusion is that fermentation can change the alkaloid profile, not that it reliably maximizes or removes mesembrenone. “Fermented Kanna” is a process description rather than a quantitative specification.
Processing sources: Patnala and Kanfer, 2009, Chen and Viljoen, 2019, and Koroleva et al., 2024.
Mesembrenone is not Δ7-mesembrenone
Mesembrenone and Δ7-mesembrenone share the formula C17H21NO3 and the same exact molecular mass. Their carbon–carbon double bonds occupy different positions. That positional difference can affect chromatographic retention, fragmentation, stability and biological activity.
A low-resolution mass signal alone may not distinguish them. Reliable assignment can require chromatographic separation, authenticated standards, diagnostic fragments and, for structural confirmation, techniques such as nuclear magnetic resonance. A result reported as “mesembrenone” should therefore be read in light of the method and the nomenclature used at the time.
Nonaqueous capillary electrophoresis coupled with mass spectrometry has been used to separate isobaric Kanna alkaloids, double-bond isomers and diastereomers across plant and product samples. The analytical lesson is broader than one method: same formula does not mean same compound.
Analytical source: Kanna alkaloid separation by nonaqueous capillary electrophoresis–MS.
How laboratories identify and quantify mesembrenone
A credible test begins with the sample matrix and the question. Plant material, fermented material, dry extracts, liquids and plasma require different extraction procedures and validation. High-performance or ultra-high-performance liquid chromatography can separate alkaloids before photodiode-array or mass-spectrometric detection. Tandem mass spectrometry adds fragment information; high-resolution instruments improve exact-mass discrimination.
Method validation should address selectivity, calibration range, accuracy, precision, recovery, matrix effects, stability, carryover and detection or quantification limits as appropriate. Reference standards need documented identity and purity. Retention time plus a single nominal mass is weak evidence when positional isomers and related alkaloids are present.
A useful certificate of analysis identifies the lot and sample type, states the method and units, reports individual alkaloids rather than only “total alkaloids,” and distinguishes “not detected” from zero. It should say whether results refer to plant mass, extract mass, liquid volume or a finished unit. Without those details, percentages from different products cannot be meaningfully compared.
Mesembrenone, medicines and interaction uncertainty
Mesembrenone’s SERT activity creates a biologically plausible reason for caution around serotonergic medicines and substances. Its metabolism through CYP2C9, CYP2C19, CYP2D6 and CYP3A4 in laboratory systems creates additional questions. However, this review did not locate controlled human interaction studies that quantified isolated mesembrenone with an antidepressant, monoamine oxidase inhibitor, stimulant or major CYP substrate.
That gap supports neither “the combination is proven safe” nor “an interaction is certain.” A substrate can be metabolized by an enzyme without meaningfully inhibiting it, and an in-vitro target result does not quantify clinical risk. Product composition, co-exposures, health conditions and individual metabolism also matter.
Someone using a serotonergic or other prescription medicine should discuss Kanna with the prescribing clinician or pharmacist rather than changing medication independently. High fever, severe agitation or confusion, repeated clonus, marked rigidity, seizure, collapse, breathing difficulty or inability to wake requires urgent medical attention. This is recognition guidance, not a home-treatment protocol.
What the evidence does and does not show
| Claim | Evidence-based reading |
|---|---|
| “Mesembrenone is Kanna.” | Incorrect. It is one possible alkaloid in a chemically variable botanical mixture. |
| “Mesembrenone is the same as mesembrine.” | Incorrect. They are distinct molecules with different relative SERT and PDE4 profiles. |
| “Mesembrenone is a natural SSRI and PDE4 drug.” | Misleading. It affected both targets in preclinical assays but lacks an approved medicine’s human clinical dossier. |
| “Human Kanna trials prove isolated mesembrenone works.” | Incorrect. The identified human studies tested multi-constituent standardized extracts. |
| “Poor oral exposure in mice proves people absorb none.” | Incorrect. The mouse result is formulation-, method-, route- and species-specific. |
| “Fermentation always raises mesembrenone.” | Unsupported. Different controlled processes produced different changes and isomer patterns. |
| “Mesembrenone and Δ7-mesembrenone are synonyms.” | Incorrect. They are positional isomers that require adequate analytical separation. |
| “CYP metabolism proves a clinical drug interaction.” | Incorrect. Enzyme involvement in metabolism does not quantify inhibition, induction or human interaction magnitude. |
Important evidence gaps
- Validated human plasma pharmacokinetics for isolated mesembrenone.
- Human bioavailability, tissue distribution and target-engagement measurements.
- Controlled human dose–response and clinical-outcome studies of the isolated molecule.
- Direct interaction studies with serotonergic medicines and clinically important CYP substrates.
- Independent replication of the major SERT and PDE4 assay findings.
- Comparative studies across authenticated plant chemotypes, controlled fermentation methods and standardized extracts.
- Long-duration safety surveillance tied to analytically verified products.
- Routine methods that clearly distinguish mesembrenone from Δ7-mesembrenone and other related compounds in complex products.
These gaps do not erase the compound’s pharmacology. They define the distance between an interesting laboratory signal and a reliable human conclusion.
Frequently asked questions
Is mesembrenone the same as mesembrine?
No. They are related but chemically distinct Kanna alkaloids. In one direct laboratory comparison, mesembrine showed much higher SERT affinity, while mesembrenone was the stronger PDE4 inhibitor.
Is mesembrenone the same as Δ7-mesembrenone?
No. They have the same formula and mass but differ in the position of a double bond. An analytical method must separate or otherwise distinguish them before assigning identity confidently.
Does mesembrenone inhibit PDE4?
Purified mesembrenone inhibited PDE4 in a preclinical assay and was more active than mesembrine and mesembrenol in that comparison. This does not establish a clinical benefit, human exposure target or equivalence to an approved PDE4 medicine.
Is mesembrenone an SSRI?
It is more accurate to say that purified mesembrenone interacted with SERT in laboratory assays. It is not an approved SSRI medicine and lacks the corresponding isolated-compound human clinical evidence.
Has isolated mesembrenone been tested in people?
This review did not identify a controlled human pharmacokinetic or outcome study of purified mesembrenone. Human Kanna studies used multi-constituent standardized extracts.
Does fermentation increase mesembrenone?
Not predictably. Studies using different plant material and processes have reported decreases, isomer shifts and other time-dependent changes. Batch-specific testing is needed.
Can Kanna or mesembrenone be combined with antidepressants?
Direct controlled human interaction data are lacking. Because mesembrenone and other Kanna alkaloids affect monoamine-related targets in laboratory studies, people using serotonergic medicines should consult the prescribing clinician or pharmacist rather than combining products or changing treatment independently.
What should a mesembrenone certificate of analysis show?
It should identify the batch and matrix, report mesembrenone separately with clear units, name the analytical method and ideally show that relevant isomers were adequately separated. “Total alkaloids” alone does not establish mesembrenone content.
Bottom line
Mesembrenone is a distinct Kanna alkaloid whose best-supported scientific feature is a dual preclinical profile: measurable SERT activity and comparatively stronger PDE4 inhibition than mesembrine or mesembrenol in one influential assay set. Metabolism work identifies several transformation pathways and candidate CYP enzymes, while mouse research provides a validated plasma method and species-specific evidence of poor oral exposure under its conditions.
The missing link is living-human evidence for isolated mesembrenone. Existing human studies used multi-constituent Kanna extracts, so they cannot establish the molecule’s pharmacokinetics, benefits, safety or interaction magnitude. Product claims should therefore remain tied to authenticated material, measured composition, tested preparation and study design.
Reviewed September 15, 2026. This educational article is for adults 21+ and is not medical advice.